Results for translational translation from English to Maltese

translational research
riċerka traslazzjonali

post-translational modification
modifika posttraduzzjonali

translational and applied research
riċerka translazzjonali u applikata

translational research in infectious diseases.
riċerka ta' konverżjoni fil-mard infettiv.

translational research in other major diseases.
riċerka tat-trasferiment fuq mard serju ieħor.

some €1.4 billion was devoted to translational cancer research from 2007 to 2013.
xi eur 1.4 biljun ġew iddedikati għal riċerka translazzjonali dwar il-kanċer mill-2007 sal-2013.

of this, €40 million specifically tackled a translational approach to the study of ad21.
minn dan l-ammont, €40 miljun indirizzaw b'mod speċifiku approċċ ta' applikazzjoni għall-istudju tal-ad21.

translational research in major infectious diseases: to confront major threats to public health.
riċerka tat-trasferiment fuq mard serju li jittieħed: sabiex jiġi kkonfrontat theddid serju għas-saħħa pubblika.

it will foster translational health research, which is essential to ensure practical benefits from biomedical research.
se ttejjeb ir-riċerka tat-trasferiment fis-saħħa, li hija essenzjali sabiex tiżgura benefiċċji prattiċi mir-riċerka bijomedika.

a comprehensive cancer approach should include all aspects of cancer research, ranging from prevention to translational and clinical research.
strateġija komprensiva għandha tinkludi l-aspetti kollha tar-riċerka dwar il-kanċer, li tvarja mill-prevenzjoni sar-riċerka ta' konverżjoni u riċerka klinika.

research on graphene is an example of an emerging translational nanotechnology where discoveries in academic laboratories are rapidly transferred to applications and commercial products.
ir-riċerka dwar il-grafen hija eżempju tan-nanoteknoloġija traslazzjonali emerġenti fejn fl-iskoperti fil-laboratorji akkademiċi huma ttrasferiti malajr għal applikazzjonijiet u prodotti kummerċjali.

identification of gaps in research and methodology, enhancement of research cooperation to avoid duplication of efforts and strengthening research on prevention and translational research;
l-identifikazzjoni ta' differenzi fir-riċerka u l-metodoloġija, it-titjib tal-kooperazzjoni fir-riċerka biex tiġi evitata d-duplikazzjoni tal-isforzi u t-tisħiħ tar-riċerka dwar il-prevenzjoni u r-riċerka ta' konverżjoni;

b-domain deleted) and similar post-translational modifications to those of the plasma-derived molecule.
b- domain mħassar), u modifikazzjoniet ta’ wara l-bidla, simili għal molekula derivata mill-plażma.

the difference in structure between them is due to post-translational events (such as different glycosylation patterns) or different tertiary structures,
id-differenza fl-istruttura bejniethom hi minħabba ġrajjiet ta' wara t-traduzzjoni (per eżempju patterns ta' glikoilazzjoni differenti) jew strutturi terzjarji,

this glycoprotein has the same structure as human factor viii when activated, and post-translational modifications that are similar to those of the plasma-derived molecule.
din il-glikoproteina għandha l-istess struttura tal-fattur viii tal-bniedem meta tiġi attivata, u modifikazzjonijiet post-traslazzjonali li jixbhu lil dawk tal-molekula derivata mill-plażma.

(2) identify needs and priorities for basic, clinical and translational research in the field of rare diseases, as well as priorities for social research;
(6) jidentifikaw il-bżonnijiet u l-prijoritajiet għal riċerka bażika, klinikali u translazzjonali fil-qasam tal-mard rari, kif ukoll prijoritajiet għal riċerka soċjali;

significant advances in translational health research, which is essential to ensure that biomedical research provides practical benefits and improves life quality, also requires multidisciplinary and pan-european approaches involving different stakeholders.
avvanzi sinifikanti fir-riċerka ta’ konverżjoni fil-qasam tas-saħħa, li hija essenzjali sabiex jiġi żgurat li r-riċerka bijomedika tipprovdi benefiċċji prattiċi u ttejjeb il-kwalità tal-ħajja, tirrikjedi wkoll strateġiji multidixxiplinari u pan-ewropej, bl-involviment ta’ diversi partijiet interessati.

endangered species can only be used for translational/applied research and testing, but not for basic research and stray and feral domestic animals cannot be used, nor can animals taken from the wild unless a specific scientific justification is provided.
l-annimali maħrubin u slavaġ ta’ speċijiet domestiċi ma jistgħux jintużaw u l-anqas ma jistgħu jinqabdu annimali mis-selvaġġ sa kemm ma jkunx hemm ġustifikazzjoni xjentifika speċifika.

the emphasis will be on translational research (transposing basic findings into clinical applications), developing and validating new treatments, identifying ways of promoting health and preventing illness, diagnostic tools and technologies for making diagnoses, as well as sustainable and effective healthcare systems.
l-enfasi se jitqiegħed fuq ir-riċerka ta’ traduzzjoni (it-trasponiment tas-sejbiet bażiċi f’applikazzjonijiet kliniċi), l-iżvilupp u l-validazzjoni ta’ trattamenti ġodda, il-metodi għall-promozzjoni tas-saħħa u l-prevenzjoni, għodod u teknoloġiji dijanjostiċi, kif ukoll sistemi sostenibbli u effikaċji għall-kura tas-saħħa.